The Functionality, Evidence, and Privacy Issues Around Smartphone Apps for the Top Neuropsychiatric Conditions
Overview
Psychiatry
Affiliations
Objective: There are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and intervention), the data collected, and any privacy policies.
Methods: This was a cross-sectional study of apps for the five most disabling neuropsychiatric conditions per the World Health Organization: stroke, migraine, depression, Alzheimer's disease and dementia, and anxiety. Up to 15 apps in the U.S. Google Play and Apple app stores were selected based on the following prespecified inclusion criteria: the app appeared in the top 50 search results, offered intervention or tracking capabilities, and listed the condition in the app title or description. Exclusion criteria were <$5.00 to purchase, solely motor versus cognitive-based intervention, or designed for use by caregivers or health care providers. Data abstracted included function, behavior change rewards, and information about intervention, privacy policy, and payment.
Results: Eighty-three apps were reviewed (stroke, N=8; migraine, N=25; Alzheimer's disease and dementia, N=8; depression, N=7; anxiety, N=14; apps targeting depression and anxiety, N=21). Sixty-nine percent of apps had an intervention component, 18% were deemed evidence based, 77% had a privacy policy, 70% required payment for access to all features, and 19% rewarded user behavior changes.
Conclusions: Most apps on the market targeted migraine, depression, and anxiety and contained interventions, although most of the interventions did not appear to be evidence based. Additionally, although most apps had privacy policies, lay people may have difficulty understanding these policies due to their complexities.
Piendel L, Valis M, Hort J Front Aging Neurosci. 2023; 15:1134096.
PMID: 37323138 PMC: 10267974. DOI: 10.3389/fnagi.2023.1134096.
Problems and Barriers Related to the Use of Digital Health Applications: Scoping Review.
Giebel G, Speckemeier C, Abels C, Plescher F, Borchers K, Wasem J J Med Internet Res. 2023; 25:e43808.
PMID: 37171838 PMC: 10221513. DOI: 10.2196/43808.
Developments in scalable strategies for detecting early markers of cognitive decline.
Whelan R, Barbey F, Cominetti M, Gillan C, Rosicka A Transl Psychiatry. 2022; 12(1):473.
PMID: 36351888 PMC: 9645320. DOI: 10.1038/s41398-022-02237-w.
Minen M, George A, Camacho E, Yao L, Sahu A, Campbell M JMIR Mhealth Uhealth. 2022; 10(6):e36761.
PMID: 35727625 PMC: 9257611. DOI: 10.2196/36761.
Funnell E, Spadaro B, Martin-Key N, Metcalfe T, Bahn S Front Psychiatry. 2022; 13:857304.
PMID: 35573342 PMC: 9091910. DOI: 10.3389/fpsyt.2022.857304.